Cargando…

High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients

BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme that is involved in prostate tumorigenesis and cancer metastasis. The predictive power of the preoperative clinical and pathological indicators for prostate cancer(PC) remains to be improved. To enrich evidence regarding the value of M...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lingxiao, Xiong, Wei, Qi, Lin, He, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318740/
https://www.ncbi.nlm.nih.gov/pubmed/37403079
http://dx.doi.org/10.1186/s12894-023-01285-8
_version_ 1785068103603847168
author Chen, Lingxiao
Xiong, Wei
Qi, Lin
He, Wei
author_facet Chen, Lingxiao
Xiong, Wei
Qi, Lin
He, Wei
author_sort Chen, Lingxiao
collection PubMed
description BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme that is involved in prostate tumorigenesis and cancer metastasis. The predictive power of the preoperative clinical and pathological indicators for prostate cancer(PC) remains to be improved. To enrich evidence regarding the value of MAOA as a prognostic biomarker in clinical practice, this study explored the significance of MAOA expression as a prognostic marker for patients with PC after radical prostatectomy-pelvic lymph node dissection (RP-PLND). METHODS: MAOA expression was analyzed in 50 benign prostate tissues and 115 low-intermediate risk and 163 high-risk PC tissues using tissue immunohistochemistry (IHC). Propensity score matching, survival analysis and COX regression analysis were conducted to investigate the correlation between high MAOA expression and progression free survival (PFS) in PC patients. RESULTS: MAOA expression was increased in PC patients, especially in those with high risk PC and pathological lymph node (pLN) metastasis. High MAOA expression was significantly associated with PSA recurrence for both low-intermediate risk PC patients (log-rank test: P = 0.02) and high risk PC patients (log-rank test: P = 0.03). Cox regression analysis revealed that high MAOA expression was an adverse prognostic factor for both low-intermediate risk PC patients (hazard ratio [HR] 2.74, 95% confidence interval [CI] 1.26–5.92; P = 0.011) and high risk PC patients (HR 1.73, 95% CI 1.11–2.71; P = 0.016). High MAOA expression was also significantly associated with PSA recurrence in high risk PC patients developed into castration-resistant prostate cancer (CRPC) and were receiving abiraterone therapy (log-rank: P = 0.01). CONCLUSIONS: MAOA expression correlates with the malignant progression of PC. High MAOA expression may be a poor prognostic marker for patients with PC after RP-PLND. More careful follow up or potential of adjuvant hormonal therapy may be addressed for patients with high MAOA expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01285-8.
format Online
Article
Text
id pubmed-10318740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103187402023-07-05 High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients Chen, Lingxiao Xiong, Wei Qi, Lin He, Wei BMC Urol Research BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme that is involved in prostate tumorigenesis and cancer metastasis. The predictive power of the preoperative clinical and pathological indicators for prostate cancer(PC) remains to be improved. To enrich evidence regarding the value of MAOA as a prognostic biomarker in clinical practice, this study explored the significance of MAOA expression as a prognostic marker for patients with PC after radical prostatectomy-pelvic lymph node dissection (RP-PLND). METHODS: MAOA expression was analyzed in 50 benign prostate tissues and 115 low-intermediate risk and 163 high-risk PC tissues using tissue immunohistochemistry (IHC). Propensity score matching, survival analysis and COX regression analysis were conducted to investigate the correlation between high MAOA expression and progression free survival (PFS) in PC patients. RESULTS: MAOA expression was increased in PC patients, especially in those with high risk PC and pathological lymph node (pLN) metastasis. High MAOA expression was significantly associated with PSA recurrence for both low-intermediate risk PC patients (log-rank test: P = 0.02) and high risk PC patients (log-rank test: P = 0.03). Cox regression analysis revealed that high MAOA expression was an adverse prognostic factor for both low-intermediate risk PC patients (hazard ratio [HR] 2.74, 95% confidence interval [CI] 1.26–5.92; P = 0.011) and high risk PC patients (HR 1.73, 95% CI 1.11–2.71; P = 0.016). High MAOA expression was also significantly associated with PSA recurrence in high risk PC patients developed into castration-resistant prostate cancer (CRPC) and were receiving abiraterone therapy (log-rank: P = 0.01). CONCLUSIONS: MAOA expression correlates with the malignant progression of PC. High MAOA expression may be a poor prognostic marker for patients with PC after RP-PLND. More careful follow up or potential of adjuvant hormonal therapy may be addressed for patients with high MAOA expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01285-8. BioMed Central 2023-07-04 /pmc/articles/PMC10318740/ /pubmed/37403079 http://dx.doi.org/10.1186/s12894-023-01285-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Lingxiao
Xiong, Wei
Qi, Lin
He, Wei
High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title_full High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title_fullStr High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title_full_unstemmed High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title_short High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
title_sort high monoamine oxidase a expression predicts poor prognosis for prostate cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318740/
https://www.ncbi.nlm.nih.gov/pubmed/37403079
http://dx.doi.org/10.1186/s12894-023-01285-8
work_keys_str_mv AT chenlingxiao highmonoamineoxidaseaexpressionpredictspoorprognosisforprostatecancerpatients
AT xiongwei highmonoamineoxidaseaexpressionpredictspoorprognosisforprostatecancerpatients
AT qilin highmonoamineoxidaseaexpressionpredictspoorprognosisforprostatecancerpatients
AT hewei highmonoamineoxidaseaexpressionpredictspoorprognosisforprostatecancerpatients